Stuttgart - Delayed Quote EUR

TMDX.SG,0P0001QO8J,60 (TMDX.SG)

141.00

+8.25

+(6.21%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025.

PR Newswire 10 days ago

TMDX
Scorpion Capital shorts TransMedics, alleging fraud in report

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The investment firm alleges fraudulent practices at TransMedics, describing it as "the most extreme and grotesque healthcare fraud we have encountered." Market Domination hosts Julie Hyman and Josh Lipton examine the details behind these allegations. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

Yahoo Finance Video 12 days ago

TMDX
Should We Be Delighted With TransMedics Group, Inc.'s (NASDAQ:TMDX) ROE Of 16%?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 14 days ago

TMDX
TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 2:15 p.m. Pacific Standard Time / 5:15 p.m. Eastern Standard Time.

PR Newswire 30 days ago

TMDX
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. T

PR Newswire last month

TMDX
TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive empl

PR Newswire last month

TMDX
TransMedics to Host Investor & Analyst Day on December 10, 2024

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.

PR Newswire last month

TMDX
TransMedics Group's (NASDAQ:TMDX) investors will be pleased with their massive 349% return over the last five years

The last three months have been tough on TransMedics Group, Inc. ( NASDAQ:TMDX ) shareholders, who have seen the share...

Simply Wall St. last month

TMDX
TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024, at 4:00 p.m. Eastern Time.

PR Newswire 2 months ago

TMDX
TransMedics Group Third Quarter 2024 Earnings: Misses Expectations

TransMedics Group ( NASDAQ:TMDX ) Third Quarter 2024 Results Key Financial Results Revenue: US$108.8m (up 64% from 3Q...

Simply Wall St. 2 months ago

TMDX
TransMedics Reports Third Quarter 2024 Financial Results

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024.

PR Newswire 2 months ago

TMDX
TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

PR Newswire 3 months ago

TMDX
There's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Simply Wall St. 3 months ago

TMDX
The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400:

PR Newswire 3 months ago

SITC

SITC-PA

TMDX
An Intrinsic Calculation For TransMedics Group, Inc. (NASDAQ:TMDX) Suggests It's 49% Undervalued

Key Insights The projected fair value for TransMedics Group is US$304 based on 2 Stage Free Cash Flow to Equity Current...

Simply Wall St. 4 months ago

TMDX
TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Eastern Time.

PR Newswire 4 months ago

TMDX
Can TransMedics Group, Inc. (NASDAQ:TMDX) Improve Its Returns?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. 5 months ago

TMDX
TransMedics Group, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

TransMedics Group, Inc. ( NASDAQ:TMDX ) just released its second-quarter report and things are looking bullish. It was...

Simply Wall St. 5 months ago

TMDX
TransMedics Reports Second Quarter 2024 Financial Results

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024.

PR Newswire 5 months ago

TMDX
TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 13, 2024, at 9:30 a.m. Eastern Standard Time.

PR Newswire 5 months ago

TMDX

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TMDX.SG,0P0001QO8J,60 (TMDX.SG)

TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report

Scorpion Capital shorts TransMedics, alleging fraud in report

Should We Be Delighted With TransMedics Group, Inc.'s (NASDAQ:TMDX) ROE Of 16%?

TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

TransMedics to Host Investor & Analyst Day on December 10, 2024

TransMedics Group's (NASDAQ:TMDX) investors will be pleased with their massive 349% return over the last five years

TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference

TransMedics Group Third Quarter 2024 Earnings: Misses Expectations

TransMedics Reports Third Quarter 2024 Financial Results

TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024

There's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital

The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

An Intrinsic Calculation For TransMedics Group, Inc. (NASDAQ:TMDX) Suggests It's 49% Undervalued

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Can TransMedics Group, Inc. (NASDAQ:TMDX) Improve Its Returns?

TransMedics Group, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

TransMedics Reports Second Quarter 2024 Financial Results

TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference